The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassemia.
Medical researchers who are interested in initiating a thalassemia-related project or who have an existing project that requires additional funding: The Cooley’s Anemia Foundation may be just what you need.
CAF has a decades-long history of supporting innovative and important research in thalassemia. Our established and respected Medical Fellowship program has funded numerous early career individuals who have continued to stay in the thalassemia field and make important contributions to the scientific and clinical study of thalassemia.
Our Support for Ongoing Clinical Research in Thalassemia Grants and Clinical Trials in Thalassemia Cell and Gene Therapy Grants are aggressively pushing forward the understanding of issues of concern to the growing thalassemia population and helping to propel advances in areas of primary importance.
The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassemia.
The Eleventh Cooley’s Anemia Symposium will bring together basic scientists, clinical investigators, and clinicians to review and discuss recent research for thalassemia syndromes.
bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.
CAF is pleased to announce one new Cooley’s Anemia Foundation Medical Research Fellowship and one renewal Fellowship have been awarded for the 2022-2023 grant cycle. The total amount of funding for the two research Fellowships is $100,000.
November 3, 2021 – The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassemia. The awards are in three categories: Support for Ongoing Clinical Research in Thalassemia Research Fellowships Clinical Trials in Thalassemia Cell and Gene Therapy Details are as follows: Support for Ongoing Clinical Research in […]
May 1, 2019 – This past Monday at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Washington, D.C., Orchard Therapeutics presented positive results from its gene therapy trial for the treatment of beta thalassemia. During this study, nine transfusion-dependent beta thalassemia patents received OTL-300 gene therapy treatment, and all nine treated […]
CAF is pleased to announce that five new Cooley’s Anemia Foundation Medical Research Fellowships and two renewal Fellowships have been awarded for the 2018-2019 grant cycle. The total amount of funding for the 7 research Fellowships is $227,500. These Fellowship recipients were assessed on the basis of the quality of the scientific content, the academic […]
September 20, 2018 – The START study is examining the effects of giving early treatment of deferiprone to young children with beta thalassemia who have started receiving regular blood transfusions but have not yet reached the criteria for starting on iron chelation therapy. There are 2 trial sites in the US: Los Angeles and Philadelphia. Learn […]
